MX2020011172A - Tratamiento de enfermedades o trastornos de la piel mediante el suministro de anticuerpo anti receptor de oncostatina m subunidad beta (osmr beta). - Google Patents
Tratamiento de enfermedades o trastornos de la piel mediante el suministro de anticuerpo anti receptor de oncostatina m subunidad beta (osmr beta).Info
- Publication number
- MX2020011172A MX2020011172A MX2020011172A MX2020011172A MX2020011172A MX 2020011172 A MX2020011172 A MX 2020011172A MX 2020011172 A MX2020011172 A MX 2020011172A MX 2020011172 A MX2020011172 A MX 2020011172A MX 2020011172 A MX2020011172 A MX 2020011172A
- Authority
- MX
- Mexico
- Prior art keywords
- pruritus
- chronic
- treatment
- disorders
- disease
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2866—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
- A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
- C07K2317/522—CH1 domain
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
- C07K2317/524—CH2 domain
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
- C07K2317/526—CH3 domain
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
- C07K2317/53—Hinge
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/52—Assays involving cytokines
- G01N2333/54—Interleukins [IL]
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
- G01N2333/715—Assays involving receptors, cell surface antigens or cell surface determinants for cytokines; for lymphokines; for interferons
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Molecular Biology (AREA)
- Dermatology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Microbiology (AREA)
- Biomedical Technology (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Mycology (AREA)
- Endocrinology (AREA)
- Food Science & Technology (AREA)
- Biotechnology (AREA)
- Cell Biology (AREA)
- Pathology (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- General Physics & Mathematics (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (9)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862662607P | 2018-04-25 | 2018-04-25 | |
| US201862718324P | 2018-08-13 | 2018-08-13 | |
| US201862765033P | 2018-08-16 | 2018-08-16 | |
| US201862731618P | 2018-09-14 | 2018-09-14 | |
| US201862757047P | 2018-11-07 | 2018-11-07 | |
| US201862775350P | 2018-12-04 | 2018-12-04 | |
| US201962789434P | 2019-01-07 | 2019-01-07 | |
| US201962794356P | 2019-01-18 | 2019-01-18 | |
| PCT/IB2019/000619 WO2019229525A2 (en) | 2018-04-25 | 2019-04-25 | TREATMENT OF SKIN DISEASES OR DISORDERS BY DELIVERY OF ANTI-OSMRβ ANTIBODY |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2020011172A true MX2020011172A (es) | 2021-01-29 |
Family
ID=68234020
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2020011172A MX2020011172A (es) | 2018-04-25 | 2019-04-25 | Tratamiento de enfermedades o trastornos de la piel mediante el suministro de anticuerpo anti receptor de oncostatina m subunidad beta (osmr beta). |
| MX2025006542A MX2025006542A (es) | 2018-04-25 | 2020-10-22 | Anticuerpo anti receptor de oncostatina m subunidad beta (osmr beta) para usarse en el tratamiento de enfermedades o trastornos de la piel |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2025006542A MX2025006542A (es) | 2018-04-25 | 2020-10-22 | Anticuerpo anti receptor de oncostatina m subunidad beta (osmr beta) para usarse en el tratamiento de enfermedades o trastornos de la piel |
Country Status (12)
| Country | Link |
|---|---|
| US (3) | US20210054085A1 (enExample) |
| EP (1) | EP3784347A2 (enExample) |
| JP (2) | JP2021522241A (enExample) |
| KR (2) | KR102849806B1 (enExample) |
| CN (2) | CN112533675A (enExample) |
| AU (2) | AU2019276779A1 (enExample) |
| BR (1) | BR112020021739A2 (enExample) |
| CA (1) | CA3096582A1 (enExample) |
| IL (1) | IL326629A (enExample) |
| MX (2) | MX2020011172A (enExample) |
| SG (1) | SG11202010034WA (enExample) |
| WO (1) | WO2019229525A2 (enExample) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TWI871349B (zh) * | 2020-09-01 | 2025-02-01 | 日商中外製藥股份有限公司 | 含有il-31拮抗劑作為有效成分之透析搔癢症的預防用及/或治療用醫藥組合物 |
| CA3189847A1 (en) * | 2020-09-01 | 2022-03-10 | Naoki Fukazawa | Pharmaceutical composition for prevention and/or treatment of dialysis pruritus containing il-31 antagonist as active ingredient |
| TW202607038A (zh) | 2020-10-19 | 2026-02-16 | 美商碩騰服務公司 | 犬及貓抑瘤素Ｍ受體β之抗體及其用途 |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP4927762B2 (ja) * | 2005-02-14 | 2012-05-09 | ザイモジェネティクス， インコーポレイテッド | Ｉｌ−３１アンタゴニストに対するアトピー性皮膚炎の治療応答を予測する方法 |
| AU2012202218B2 (en) * | 2005-02-14 | 2014-05-22 | National Jewish Medical And Research Center | Methods Of Treating Diseases Which Are Mediated By Cutaneous Lymphocyte Antigen Positive Cells |
| US9475876B2 (en) * | 2012-05-11 | 2016-10-25 | Wakayama Medical University | Anti oncostatin M receptor beta antibody used for treating atopic dermatitis |
| HUE056580T2 (hu) * | 2013-05-30 | 2022-02-28 | Kiniksa Pharmaceuticals Ltd | Onkosztatin-M-receptor antigénjét kötõ fehérjék |
| TWI755763B (zh) * | 2013-06-04 | 2022-02-21 | 美商再生元醫藥公司 | 藉由投與il-4r抑制劑以治療過敏及增強過敏原-特異之免疫療法的方法 |
| EP3250599B1 (en) * | 2015-01-29 | 2021-04-14 | Oxford University Innovation Limited | Biomarker |
| FI3284480T3 (fi) * | 2015-04-14 | 2025-09-11 | Chugai Pharmaceutical Co Ltd | IL-31-antagonistia vaikuttavana ainesosana sisältävä farmaseuttinen koostumus atooppisen ihottuman ehkäisemiseksi ja/tai hoitamiseksi |
-
2019
- 2019-04-25 CN CN201980039355.2A patent/CN112533675A/zh active Pending
- 2019-04-25 EP EP19786854.0A patent/EP3784347A2/en active Pending
- 2019-04-25 IL IL326629A patent/IL326629A/en unknown
- 2019-04-25 WO PCT/IB2019/000619 patent/WO2019229525A2/en not_active Ceased
- 2019-04-25 MX MX2020011172A patent/MX2020011172A/es unknown
- 2019-04-25 KR KR1020207033800A patent/KR102849806B1/ko active Active
- 2019-04-25 CA CA3096582A patent/CA3096582A1/en active Pending
- 2019-04-25 CN CN202510495862.4A patent/CN121818914A/zh active Pending
- 2019-04-25 US US17/050,261 patent/US20210054085A1/en not_active Abandoned
- 2019-04-25 AU AU2019276779A patent/AU2019276779A1/en not_active Abandoned
- 2019-04-25 JP JP2020559390A patent/JP2021522241A/ja not_active Withdrawn
- 2019-04-25 BR BR112020021739-5A patent/BR112020021739A2/pt unknown
- 2019-04-25 KR KR1020257027582A patent/KR20250127348A/ko active Pending
- 2019-04-25 SG SG11202010034WA patent/SG11202010034WA/en unknown
-
2020
- 2020-10-22 MX MX2025006542A patent/MX2025006542A/es unknown
-
2023
- 2023-03-30 US US18/193,393 patent/US20240101690A1/en not_active Abandoned
-
2024
- 2024-04-17 JP JP2024066665A patent/JP2024096933A/ja active Pending
- 2024-10-04 US US18/907,052 patent/US20250236676A1/en active Pending
-
2026
- 2026-03-16 AU AU2026201985A patent/AU2026201985A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| AU2026201985A1 (en) | 2026-04-02 |
| US20210054085A1 (en) | 2021-02-25 |
| CN121818914A (zh) | 2026-04-10 |
| CN112533675A (zh) | 2021-03-19 |
| WO2019229525A2 (en) | 2019-12-05 |
| JP2024096933A (ja) | 2024-07-17 |
| KR20210018808A (ko) | 2021-02-18 |
| AU2019276779A1 (en) | 2020-12-10 |
| EP3784347A2 (en) | 2021-03-03 |
| US20240101690A1 (en) | 2024-03-28 |
| SG11202010034WA (en) | 2020-11-27 |
| JP2021522241A (ja) | 2021-08-30 |
| WO2019229525A3 (en) | 2020-03-19 |
| KR20250127348A (ko) | 2025-08-26 |
| MX2025006542A (es) | 2025-07-01 |
| BR112020021739A2 (pt) | 2021-01-26 |
| KR102849806B1 (ko) | 2025-08-22 |
| IL326629A (en) | 2026-04-01 |
| CA3096582A1 (en) | 2019-12-05 |
| US20250236676A1 (en) | 2025-07-24 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PH12022551169A1 (en) | METHODS OF TREATING LSD1-RELATED DISEASES and Disorders WITH LSD1 INHIBITORS | |
| BR112022000231A2 (pt) | Novos métodos | |
| MX2017005875A (es) | Metodos para tratar enfermedades oculares. | |
| MX2015008777A (es) | Crenolanib para el tratamiento de trastornos proliferativos que tienen flt3 mutado. | |
| MX2025006542A (es) | Anticuerpo anti receptor de oncostatina m subunidad beta (osmr beta) para usarse en el tratamiento de enfermedades o trastornos de la piel | |
| EA201591754A1 (ru) | Человеческие антитела к na1.7 | |
| BR112014015955A8 (pt) | uso terapêutico subcutâneo de inibidor de dpp-4 | |
| JOP20190008A1 (ar) | علاج ومنع اضطرابات النوم | |
| MX2025001920A (es) | Tratamiento de enfermedades y trastornos asociados a las mitocondrias, incluyendo los sintomas de los mismos usando pridopidina | |
| BR112015021371A2 (pt) | uso de agonistas de receptor de formil peptídeo 2 para tratar doenças inflamatórias oculares | |
| MX2017006938A (es) | Terapia de combinacion para el tratamiento de cancer. | |
| BR112017007738A2 (pt) | método para inibir a evasão imune, método para tratar disfunção imune, método para intensificar uma resposta imune, método para aumentar a expressão de um complexo de histocompatibilidade principal, método para aumentar a inflamação, método para tratar um câncer ou um distúrbio proliferativo celular, método para determinar a probabilidade de eficácia de um tratamento, e, método para triagem da eficácia de um tratamento | |
| MX2017009694A (es) | Anticuerpos anti ligando de cumulo de diferenciacion 40 (cd40l) y metodos para tratar enfermedades o trastornos relacionados al ligando de cumulo de diferenciacion 40 (cd40l). | |
| BR112018072401A2 (pt) | combinações de linagliptina e metformina | |
| BR112015010039A2 (pt) | tratamento de câncer com pomalidomida em um individuo com disfunção renal | |
| MX2021013354A (es) | Metodos para tratar y/o prevenir queratosis actinica. | |
| EP4285993A3 (en) | Growth differentiation factor 15 as biomarker for metformin | |
| AR111374A1 (es) | Uso de lik066 en pacientes con insuficiencia cardíaca | |
| MX2023002997A (es) | Metodo de tratamiento de la amiloidosis. | |
| MX389282B (es) | Composiciones y métodos para tratar sinucleinopatías. | |
| BR112015012497A2 (pt) | combinações farmacêuticas | |
| PE20200889A1 (es) | METODOS PARA EL TRATAMIENTO DE ENFERMEDADES RELACIONADAS CON TNF(alfa) | |
| EA202092545A1 (ru) | Лечение заболеваний или нарушений кожи посредством доставки антитела к osmr | |
| BR112016011811A2 (pt) | Uso de um inibidor de fosfatidilinositol 3-cinase seletivo de alfa-isoforma, regime terapêutico e pacote | |
| MX2021007324A (es) | Terapia oral con acido 6,8-bis-benciltio-octanoico. |